Clinical Trial Update: Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease [Phase 1]

View source ↗

Summary

Akros Pharma completed a Phase 1 safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) study of JTZ-951 in anemic subjects with end-stage renal di…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anemia of Chronic Kidney Disease

Drugs mentioned

• JTZ-951

Snippet

Sponsor: Akros Pharma Inc. | Conditions: Anemia of Chronic Kidney Disease | Phase 1 | Status: COMPLETED